A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL). (Part B)
A Phase 1/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CDK-003 in Healthy Adult Participants and Intralesionally Administered CDK-003 in Patients With Cutaneous T-cell Lymphoma (CTCL)
Sponsor: Codiak BioSciences
Terminated
PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety profile. Proceeding to Phase II did not require additional data from this Phase I Dose-Finding study.
Other terminated trials from Codiak BioSciences
More terminations from Codiak BioSciences
This PHASE1 trial investigates Cutaneous T-cell Lymphoma (CTCL) and is currently terminated or withdrawn. Codiak BioSciences leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — May 2022 [monthly]
Recruiting PHASE1
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Codiak BioSciences
For direct contact, visit the study record on ClinicalTrials.gov .